510(k) Report

510(k) · Cleared

Cleared

Elecsys Psa (on Elecsys 1010)

K974189510(k) TraditionalCleared Jan 6, 199860-day reviewClass II21 CFR 866.6010

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Boehringer Mannheim Corp. · LTJ Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers

Cleared on Jan 6, 1998 as substantially equivalent to K964351 (Boehringer Mannheim Corp., 1997) after a 60-day review. Its family tree reaches back 1 generation to 1997.

Decided
Jan 6, 1998
Review
60 days
Class
Class II
Product code
LTJ
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to K964351 (1997). No later device cites it as a predicate yet.

K964351 · Elecsys Psa Assay · Boehringer Mannheim Corp. · 19970
  1. Root · 1 generation backK964351 Elecsys Psa AssayBoehringer Mannheim Corp. · 1997
  2. This deviceK974189 Elecsys Psa (on Elecsys 1010)Boehringer Mannheim Corp. · 1998
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K964351Elecsys Psa AssayBoehringer Mannheim Corp.1997—
0 (this device)K974189Elecsys Psa (on Elecsys 1010)Boehringer Mannheim Corp.1998—
FIG. 1 — Lineage of K974189, 1997–1998Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LTJ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LTJ device

  1. #1 K251630 Atellica IM Total PSA II (tPSAII)score 10.6 · 1 generation · no Class I recall
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K964351Elecsys Psa Assay
Summary page 2
…sma to aid in the management of prostate cancer patients. The Boehringer Mannheim Elecsys® PSA Assay has been approved for use on the Elecsys 2010 immunoassay analyzer (K964351/S1). The application of the Elecsys® PSA Assay on the Elecsys 1010 immunoassay analyzer is substantially equivalent to the same a…
Boehringer Mannheim Corp.1997—

Also cleared against K964351: 1 other device →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.
  • 1 other device also cites its predicate K964351.

How does its category compare?

All LTJ devices

LTJ Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · LTJ

3in 2025

2013: 12016: 22017: 102018: 72019: 22020: 12021: 22023: 22024: 32025: 32026 (partial year): 3
2007high 10 (2017) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LTJ

Too few LTJ 510(k)s in any year since 2007 to give a median.

Recalls per year · LTJ

1in 2025

2008: 32010: 22013: 12025: 1
2007high 3 (2008) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LTJ

14in 2025

2007: 172008: 572009: 582010: 342011: 1092012: 1012013: 692014: 192015: 142016: 82017: 132018: 82019: 112020: 42021: 82022: 112023: 172024: 82025: 14
2007high 109 (2011) · low 4 (2020)2025

MAUDE reports naming product code LTJ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—017
20080—357
20090—058
20100—234
20110—0109
20120—0101
20131—169
20140—019
20150—014
20162—08
201710—013
20187—08
20192—011
20201—04
20212—08
20220—011
20232—017
20243—08
20253—114
20263—0—

What is it indicated for?

Immunoassay for the in vitro quantitative dctermination of Prostate-Specific Antigen (PSA)

in human serum and'plasma. The Elecsys PSA assay is further indicated for serial measure of

PSA to aid in the management of prostate cancer.

The eclectrochemiluminescence immunoassay “ECLIA™ is intended for use on the Bochnnger

Mannheim Elecsys 2010 and 1010 immunoassay analyzers.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K974189: Elecsys Psa (on Elecsys 1010).” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K974189

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026